PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of aacPermissionsJournals.ASM.orgJournalAAC ArticleJournal InfoAuthorsReviewers
 
Antimicrob Agents Chemother. May 2001; 45(5): 1605–1606.
PMCID: PMC90520
Emergence of Fluoroquinolone-Resistant Strains of Vibrio cholerae O1 Biotype El Tor among Hospitalized Patients with Cholera in Calcutta, India
Pallavi Garg, Sutapa Sinha, Rupa Chakraborty, S. K. Bhattacharya, G. Balakrish Nair, and T. Ramamurthy*
National Institute of Cholera and Infectious Diseases
P-33, CIT Rd. Scheme XM, Beliaghata
Calcutta 700 010, India
Yoshifumi Takeda
National Institute of Infectious Diseases
Shinjuku-ku, Tokyo, Japan
*Fax: 91-33-350-5066 E-mail: gbnair/at/vsnl.com
Ciprofloxacin and norfloxacin are broad-spectrum fluoroquinolones and possess excellent activity against Vibrio cholerae O1 and O139 serogroups (6). Clinical studies have shown that these drugs are effective in treatment of cholera in adults and children (24). For the past 11 years, we have been monitoring the incidence of antibiotic susceptibility and genotypic changes in V. cholerae isolates from cholera patients admitted at the Infectious Diseases Hospital, Calcutta, India. Here, we report the emergence of fluoroquinolone-resistant strains of V. cholerae O1 Biotype El Tor among hospitalized patients with cholera.
Antimicrobial susceptibility analysis of V. cholerae strains was performed by disk diffusion (1) on Mueller-Hinton agar (Difco, Detroit, Mich.) with commercial disks (HiMedia, Mumbai, India). The following antibiotic disks were used: ciprofloxacin, 5 μg; nalidixic acid, 30 μg; norfloxacin, 10 μg; and tetracycline, 30 μg. Characterization of strains as susceptible, intermediately resistant, or resistant was based on the size of the inhibition zone according to the manufacturer's instructions. These zone size interpretive criteria for susceptibility corresponded to MICs of 0.25, 0.06, and 0.06 μg/ml for nalidixic acid, norfloxacin, and ciprofloxacin, respectively. Strains showing intermediate zones of growth inhibition were classified as resistant on the basis of previous MIC studies with V. cholerae (6).
We have reported considerable increases in fluoroquinolone resistance among V. cholerae strains belonging to non-O1, non-O139 serogroups during 1996 (5). All the V. cholerae strains of serogroup O1 isolated in or before 1994 are susceptible to ciprofloxacin. From 1995, we have recorded progressive increases in ciprofloxacin and norfloxacin resistance among V. cholerae O1 strains, with the highest occurrences of 38.8% in 1999 and 25% in 2000, respectively (Table (Table1).1). To our knowledge, this is the first report on such high incidence of fluoroquinolone resistance among toxigenic V. cholerae O1 strains. The MICs of ciprofloxacin and norfloxacin for ciprofloxacin-resistant V. cholerae strains ranged between 9 and >32 μg/ml and between 192 and >256 μg/ml, respectively, when tested with the E-test strips on Mueller-Hinton agar (AB Biodisk, Solna, Sweden). The incidence of nalidixic acid resistance among V. cholerae O1 strains was low (<10%) before 1993 and peaked during subsequent years (1999; 100%), as shown in the Table Table1.1. Possibly, ciprofloxacin resistance might have emerged in direct response to the selective pressure exerted by nalidixic acid coupled with disproportionate use of fluoroquinolones in the clinical settings. It is worth to mention here that the increase in the incidence of nalidixic acid-resistant strains of V. cholerae O1 (probably with a single mutation in gyrA and/or other related genes) portended a further increase in the incidence of strains with clinically significant resistance to fluoroquinolones (with two or more mutations in the gyrA gene). We are in the process of identifying the mutational “hot spots” in the quinolone resistance-determining region.
TABLE 1
TABLE 1
Resistance to quinolones among V. cholerae O1 and O139 isolates from cholera patients
An interesting observation in the present report is the low incidence of quinolone resistance in the O139 serogroup. One possible elucidation is the low frequency of nalidixic acid resistance among V. cholerae O139 strains (Table (Table1),1), and therefore the frequency of double mutations, a prerequisite for fluoroquinolone resistance, is low, as reflected by resistance O139 strains to fluoroquinolones.
In this study we encountered a higher incidence of V. cholerae O1 resistance to ciprofloxacin than to norfloxacin, which is generally less potent than ciprofloxacin. The possible explanation for this counterintuitive result is (i) since ciprofloxacin is in extensive use for all the bacterial infections in this part of the world, conditions of high selective pressure would have forced the mutant V. cholerae strains to multiply and establish themselves as the dominant population; continued selective pressure favored these progeny to have further mutations; (ii) ciprofloxacin and norfloxacin breakpoints are not comparable, at least for V. cholerae strains (the MIC for 50% of the strains [MIC50], MIC90, and MIC ranges need to be determined for both drugs to prove this hypothesis); or (iii) ciprofloxacin and norfloxacin accumulation kinetics might differ among V. cholerae O1 strains. Additional, extensive studies are needed to test these possibilities in order to determine the mechanisms responsible for heterogeneous fluoroquinolone resistance among V. cholerae O1 strains.
Emergence of fluoroquinolone resistance in V. cholerae will certainly complicate the therapeutic use of these drugs, and attention must be paid to this trend. Fortunately, V. cholerae O1 and O139 strains are susceptible to tetracycline, which is an effective drug for treatment of cholera at the Infectious Disease Hospital.
Acknowledgments
This work was supported in part by the Japan International Cooperation Agency (JICA/NICED project 054-1061-E-O) and CSIR, India [no. 37 (1019)/99/EMR-II].
1. Bauer A W, Kirby W M, Sherris J C, Turck M. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol. 1966;45:493–496. [PubMed]
2. Bhattacharya S K, Bhattacharya M K, Dutta P, Dutta D, De S P, Sikdar S N, Maitra A, Dutta A, Pal S C. Double-blind, randomized, controlled clinical trial of norfloxacin for cholera. Antimicrob Agents Chemother. 1990;34:939–940. [PMC free article] [PubMed]
3. Dutta D, Bhattacharya S K, Bhattacharya M K, Deb A, Deb M, Manna B, Moitra A, Mukhopadhyay A K, Nair G B. Efficacy of norfloxacin and doxycycline for treatment of Vibrio cholerae O139 infection. J Antimicrob Chemother. 1996;37:575–581. [PubMed]
4. Gottuzo E, Seas C, Echevarria J, Carrillo C, Mostorino R, Ruiz R. Ciprofloxacin for the treatment of cholera: a randomized, double-blind, controlled clinical trial of a single daily dose in Peruvian adults. Clin Infect Dis. 1995;20:1485–1490. [PubMed]
5. Mukhopadhyay A K, Basu I, Bhattacharya S K, Bhattacharya M K, Nair G B. Emergence of fluoroquinolone resistance in strains of Vibrio cholerae isolated from hospitalized patients with acute diarrhea in Calcutta, India. Antimicrob Agents Chemother. 1998;42:206–207. [PMC free article] [PubMed]
6. Yamamoto T, Nair G B, Albert M J, Parodi C C, Takeda Y. Survey of in vitro susceptibilities of Vibrio cholerae O1 and O139 to antimicrobial agents. Antimicrob Agents Chemother. 1995;39:241–244. [PMC free article] [PubMed]
Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of
American Society for Microbiology (ASM)